文献速递临床试验与 GCP流行病学与生物统计

全科医生使用C反应蛋白即时检测指导慢性阻塞性肺疾病急性加重患者抗生素处方的随机对照试验(PACE研究)方案

General practitioner use of a C-reactive protein point-of-care test to help target antibiotic prescribing in patients with acute exacerbations of chronic obstructive pulmonary disease (the PACE study): study protocol for a randomised controlled trial.
PubMed 文献 · Trials · 2017-09-29

PACE研究是一项多中心、个体随机对照试验,计划纳入650例初级保健中诊断的慢性阻塞性肺疾病急性加重(AECOPD)患者,随机分为常规管理组或在常规管理基础上增加C反应蛋白即时检测(POCT)指导抗生素处方组。共同主要结局为随机化后4周内AECOPD的抗生素消耗量(优效性)和随机化后2周时慢性阻塞性肺疾病问卷(CCQ)总分(非劣效性)。

要点

  • 多中心个体随机对照试验,计划纳入650例初级保健AECOPD患者。
  • 共同主要结局:4周内AECOPD抗生素消耗量(优效性)和2周CCQ总分(非劣效性)。
  • 次要结局包括6个月内的健康相关生活质量、肺炎发生率、医疗资源使用和成本比较等。

核心结论

  • 若被证明有效(即减少抗生素使用且COPD健康状况不更差),使用C反应蛋白即时检测可能改善AECOPD患者结局并有助于减少驱动抗菌药物耐药发展的选择压力。
  • PACE将是首批评估即时检测生物标志物指导初级保健临床决策对患者报告结局、抗生素处方和AECOPD抗生素耐药性的成本效果的研究之一。

研究设计与样本

  • 多中心、个体随机对照试验,计划纳入650例在初级保健中诊断的AECOPD参与者。
  • 参与者随机分为按常规管理(对照组)或在常规管理基础上增加C反应蛋白即时检测指导抗生素处方。

主要发现

  • 主要分析(按意向性治疗)将确定抗生素消耗量的优效性差异和COPD健康状况的非劣效性差异。
  • 次要结局包括:COPD健康状况、CCQ领域评分、其他COPD治疗使用(第1、2和4周)、EQ-5D效用评分(第1、2和4周及第6个月)、6个月时疾病特异性健康相关生活质量、随机化后前4周内全因抗生素消耗(任何情况的抗生素使用)、总抗生素消耗(前4周内因AECOPD/任何原因使用抗生素的天数)、索引咨询时及随后4周内的抗生素处方、前4周内不良反应、肺炎发生率(第4周和6个月)、随机化后6个月内的医疗资源使用和成本比较。
  • 将使用基线和4周随访时收集的咽拭子和痰标本评估细菌的患病率和耐药谱。
  • 将进行健康经济学评价和定性过程评价。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Most patients presenting with acute exacerbations of chronic obstructive pulmonary disease (AECOPD) in primary care are prescribed an antibiotic, which may not always be appropriate and may cause harm. C-reactive protein (CRP) is an acute-phase biomarker that can be rapidly measured at the point of care and may predict benefit from antibiotic treatment in AECOPD. It is not clear whether the addition of a CRP point-of-care test (POCT) to clinical assessment leads to a reduction in antibiotic consumption without having a negative impact on COPD health status. METHODS/DESIGN: This is a multicentre, individually randomised controlled trial (RCT) aiming to include 650 participants with a diagnosis of AECOPD in primary care. Participants will be randomised to be managed according to usual care (control) or with the addition of a CRP POCT to guide antibiotic prescribing. Antibiotic consumption for AECOPD within 4 weeks post randomisation and COPD health status (total score) measured by the Clinical COPD Questionnaire (CCQ) at 2 weeks post randomisation will be co-primary outcomes. Primary analysis (by intention-to-treat) will determine differences in antibiotic consumption for superiority and COPD health status for non-inferiority. Secondary outcomes include: COPD health status, CCQ domain scores, use of other COPD treatments (weeks 1, 2 and 4), EQ-5D utility scores (weeks 1, 2 and 4 and month 6), disease-specific, health-related quality of life (HRQoL) at 6 months, all-cause antibiotic consumption (antibiotic use for any condition) during first 4 weeks post randomisation, total antibiotic consumption (number of days during first 4 weeks of antibiotic consumed for AECOPD/any reason), antibiotic prescribing at the index consultation and during following 4 weeks, adverse effects over the first 4 weeks, incidence of pneumonia (weeks 4 and 6 months), health care resource use and cost comparison over the 6 months following randomisation. Prevalence and resistance profiles of bacteria will be assessed using throat and sputum samples collected at baseline and 4-week follow-up. A health economic evaluation and qualitative process evaluation will be carried out. DISCUSSION: If shown to be effective (i.e. leads to a reduction in antibiotic use with no worse COPD health status), the use of the CRP POCT could lead to better outcomes for patients with AECOPD and help reduce selective pressures driving the development of antimicrobial resistance. PACE will be one of the first studies to evaluate the cost-effectiveness of a POCT biomarker to guide clinical decision-making in primary care on patient-reported outcomes, antibiotic prescribing and antibiotic resistance for AECOPD. TRIAL REGISTRATION: ISRCTN registry, ID: ISRCTN24346473 . Registered on 20 August 2014.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Bates J, Francis NA, White P, et al. General practitioner use of a C-reactive protein point-of-care test to help target antibiotic prescribing in patients with acute exacerbations of chronic obstructive pulmonary disease (the PACE study): study protocol for a randomised controlled trial. Trials. 2017. PMID: 28969667. doi:10.1186/s13063-017-2144-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。